NASDAQ OMX

Radixx International Appoints John Elieson as President and CEO

Dela

 

ORLANDO, Fla., Oct. 04, 2017 (GLOBE NEWSWIRE) -- Radixx International, an industry-leading provider of tailored airline reservation, distribution and merchandising systems, today announced that it has appointed John Elieson as President & CEO. Ron Peri, Radixx's Founder and former CEO, will continue to serve as Chairman of Radixx's Board of Directors.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/1e4e5090-f5a9-457c-8e2d-b61664ed2a78

Mr. Elieson will be responsible for implementing the overall strategic direction of Radixx and will oversee the company's daily operations. Prior to joining Radixx, Mr. Elieson spent 29 years at Sabre where he most recently served as Senior Vice President of Global Accounts and Traveler Experience in their Travel Network division. During his career at Sabre, Mr. Elieson has had a variety of responsibilities including leading global sales for Sabre's Airline Solutions division and leading Global Marketing and Corporate Strategy for Travelocity.  The majority of Mr. Elieson's distinguished career has been spent in direct and indirect airline distribution, both offline and online.

"John is the ideal fit for Radixx as the company continues to make significant strides and grow its customer base," said Ron Peri, Founder and Chairman of Radixx International. "We are confident that John's background and relevant experience within the global travel industry, particularly as they pertain to airline solutions, will prove to be of tremendous value. We are very pleased to welcome John to Radixx and look forward to his future contributions to the company."

"John is a talented leader with a proven track record for driving growth and building highly effective teams," said Kurt R. Jaggers, a member of Radixx's Board of Directors and a Managing Director at TA Associates, which completed a significant investment in Radixx in September 2016. "We believe that John's management skills and travel sector knowledge will prove beneficial for Radixx. On behalf of the Board of Directors, I would like to sincerely thank Ron Peri for his service, passion and dedication to Radixx and its customers, partners and employees, and we look forward to his continued contributions as Chairman."

Commenting on his appointment, Mr. Elieson said, "I am thrilled and grateful to have the opportunity to join Radixx, a company that I have followed and respected for many years. As a result of the hard work of both leadership and staff, Radixx is well positioned to take advantage of its leading technology and unique value proposition to significantly grow its customer base. I am impressed with the Radixx team and am eager to work closely with them to build upon the company's strong reputation and momentum."

John Elieson Biography
John Elieson is President & CEO of Radixx International. Prior to joining Radixx, Mr. Elieson served as Senior Vice President of Global Accounts and Traveler Experience for Sabre Travel Network, a technology provider to the global travel industry. He spent nearly three decades with Sabre and its former parent company, American Airlines, in a variety of functional areas including operations, training, software development, consulting, business development, sales & account management, marketing, product development, portfolio management, pricing & revenue management, business intelligence and strategy. During his tenure, Mr. Elieson successfully led several multi-billion dollar negotiations creating significant value for all parties. He earned an MBA from Vanderbilt University and has conducted business and managed staff all over the world. Mr. Elieson serves on several boards for businesses, universities, municipalities and non-profit organizations.

About Radixx International
Radixx International, Inc., headquartered in Orlando, Florida, is now delivering its sixth-generation passenger service system, Galaxy PSS. Galaxy is the first fully web-native PSS system and can be deployed in any public or private data center. It has been certified to operate from the smallest cloud network to the largest most demanding environments. Galaxy provides a customizable, complete enterprise system that caters to the needs of hybrid, low-cost and traditional airlines, including support for interlining, code sharing and distribution through GDS. Founded in 1993 and now hosting 50 airlines on six continents, Radixx' fully integrated, cloud-based solutions support all airline business models. Radixx recently partnered with TA Associates, a leading global growth private equity firm. For more information, visit www.radixx.com.

Media Contact:
John Beisner
Bond Moroch
jbeisner@bondmoroch.com
+1.504.323.8337

 
 



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Radixx Solutions International, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Bergman & Beving AB: Share-based incentive scheme25.9.2018 10:00Pressmeddelande

Press Release Share-based incentive scheme The share-based incentive scheme resolved by the 2018 Annual General Meeting where 16 members of senior management were offered to acquire up to 210,000 call options on repurchased class B shares has been fully subscribed. The call options will be transferred at a price of SEK 7.10 per call option, equivalent to the market value according to an external independent valuation, applying the Black-Scholes-model. The redemption price of the call options amounts to SEK 117.90, equivalent to 120 percent of the volume-weighted average of the paid market price for the shares during the period from 24 August to 7 September 2018, inclusive. Each call option entitles the holder to acquire one repurchased class B share during the period from 13 September 2021 to 10 June 2022, inclusive. Stockholm den 25 September 2018 Bergman & Beving AB (publ) Contact information Peter Schön, CFO, Bergman & Beving AB, Tel: +46 70 339 89 99 The information was submitted f

Bergman & Beving AB: Aktierelaterat incitamentsprogram25.9.2018 10:00Pressmeddelande

Pressrelease Aktierelaterat incitamentsprogram Det av årsstämman 2018 beslutade aktierelaterade incitamentsprogrammet som omfattar 16 ledningspersoner om maximalt 210 000 köpoptioner på återköpta aktier av serie B har fulltecknats. Köpoptionerna kommer att överlåtas till ett pris av 7,10 SEK per köpoption vilket motsvarar marknadsvärde enligt en extern oberoende värdering utförd i enlighet med Black-Scholes-modellen. Lösenkursen för köpoptionerna uppgår till 117,90 SEK motsvarande 120 procent av den genomsnittliga aktiekursen under mätperioden 24 augusti - 7 september 2018. Varje köpoption berättigar till förvärv av en återköpt aktie av serie B under perioden från och med den 13 september 2021 till och med den 10 juni 2022. Stockholm den 25 september 2018 Bergman & Beving AB (publ) För ytterligare information kontakta: Peter Schön, CFO, telefon 070-339 89 99 Informationen lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 25 september 2018 kl. 10:00 CET. Ber

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Karolinska Development's portfolio company Asarina Pharma is listed on Nasdaq First North24.9.2018 08:00Pressmeddelande

STOCKHOLM, 24 September 2018. Karolinska Development's portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm. In connection with the listing, Asarina Pharma is issuing 6.8 million shares. The issue price of SEK 21 gives Asarina Pharma a pre money valuation of SEK 172 million. Conditioned that the over-allotment option of an additional 0.35 million shares is fully exercised, Asarina Pharma will be provided with a total of SEK 150.2 million before issue costs. Asarina Pharma is a Swedish biotech company focused on chronic diseases associated with the menstrual cycle. The portfolio company is developing the drug candidate sepranolone as a treatment for premenstrual dysphoric disorder (PMDD) and premenstrual migraine. A Phase IIb study is currently underway in PMDD with expected completion by the end of 2019. Furthermore, Asarina Pharma is planning a clinical Phase IIa study in menstrual migraine for the first half of 2019. Karolinska Development is a pas

Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board17.9.2018 08:00Pressmeddelande

Press Release 17 September 2018 Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB (publ; IMMU.ST) announced today the appointment of leading oncology experts to its Scientific Advisory Board with the addition of Pawel Kalinski, MD, PhD, Vice Chair for Translational Research within the Department of Medicine at Roswell Park Comprehensive Cancer Center, and Inge Marie Svane, MD, PhD, Professor, Head of the Clinical Cancer Research programme, Faculty of Health Sciences, University of Copenhagen, Director, Centre for Cancer Immunotherapy (CCIT), and consultant in Oncology, Herlev University Hospital. Both Scientific Advisory Board members will serve as a strategic resource to Immunicum as the company continues to advance the clinical development of its lead product, ilixadencel. "We are honored to have such highly specialized experts in the field of immuno-oncology and cell therapy join our Scientific Advisory Board a

Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet17.9.2018 08:00Pressmeddelande

Pressmeddelande 17 september 2018 Immunicum AB (publ) meddelar att Pawel Kalinski och Inge Marie Svane har valts in i det vetenskapliga rådet Immunicum AB (publ; IMMU.ST) meddelade i dag att två ledande immun-onkologiska experter har valts in i bolagets vetenskapliga råd för att fungera som strategiska resurser för Immunicum under bolagets fortsatta kliniska utveckling av sin ledande produkt, ilixadencel. Pawel Kalinski, MD, PhD, vice ordförande för translationell forskning vid den medicinska institutionen vid Roswell Park Comprehensive Cancer Center, och Inge Marie Svane, MD, PhD, professor, chef för det kliniska cancerforskningsprogrammet på medicinska fakulteten vid Köpenhamns universitet, chef för Center för cancerimmunterapi (CCIT) samt överläkare inom onkologi, Herlevs universitetssjukhus har valts in i rådet. - Vi är hedrade att ha experter med specialistkompetens inom området immunonkologi och cellterapi i vårt vetenskapliga råd, vilka kan erbjuda ytterligare vägledning när det

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum